Lijuan Jiang

机构：Wuhan Union Hospital, Enanta Pharmaceuticals (United States) · ORCID：0000-0002-8666-0477

发表论文 32 篇 · 总被引 317 次 · h-index 10

代表论文

Enhanced recovery after surgery for radical cystectomy with ileal urinary diversion: a multi-institutional, randomized, controlled trial from the Chinese bladder cancer consortium (2017 · World Journal of Urology · 被引 61)
The diagnostic values of C-reactive protein and procalcitonin in identifying systemic lupus erythematosus infection and disease activity (2019 · Medicine · 被引 51)
LncRNA CCAT1 negatively regulates miR‑181a‑5p to promote endometrial carcinoma cell proliferation and migration (2019 · Experimental and Therapeutic Medicine · 被引 34)
Interaction between BMSCs and EPCs promotes IUA angiogenesis via modulating PI3K/Akt/Cox2 axis. (2018 · PubMed · 被引 27)
Predictive value of procalcitonin for diagnosis of infections in patients with chronic kidney disease: a comparison with traditional inflammatory markers C-reactive protein, white blood cell count, and neutrophil percentage (2017 · International Urology and Nephrology · 被引 27)
First‐line programmed death receptor‐1 ( PD ‐1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum‐based chemotherapy, for stage IV penile cancer (2022 · British Journal of Urology · 被引 22)